Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | DRD3 | P35462 | 4/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565555 | 0.93 | AR (0.69) | ARNR3C1ESR1ESR2ALDH1A1 | |
| SCHEMBL3910141 | 0.88 | AR (0.72) | ARNR3C1ALDH1A1LMNACYP3A4 | |
| SCHEMBL12272182 | 0.86 | AR (0.60) | ARNR3C1ESR1ESR2ALDH1A1 | |
| SCHEMBL6247392 | 0.84 | AR (0.64) | ARNR3C1ESR1ESR2ALDH1A1 | |
| SCHEMBL3910326 | 0.81 | AR (0.67) | ARNR3C1ALDH1A1LMNACYP3A4 | |
| SCHEMBL12273326 | 0.81 | AR (0.63) | ARNR3C1ALDH1A1LMNAKDM1A | |
| SCHEMBL12272913 | 0.81 | AR (0.63) | ARNR3C1ALDH1A1LMNAKDM1A | |
| SCHEMBL12272588 | 0.81 | AR (0.63) | ARNR3C1ALDH1A1LMNAKDM1A | |
| SCHEMBL6251089 | 0.81 | AR (0.47) | ARESR1ESR2KDM1ABACE1 | |
| SCHEMBL3288674 | 0.80 | AR (1.00) | ARNR3C1ESR2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399406-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS I | KAROBIO AB (SE) | 2005-08-10 | — | — | EP | disclosed |
| US-20040127576-A1 | Estrogen receptor modulators | KARO BIO AB (SE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127576-A1 | Estrogen receptor modulators | GPER1, ESRRA, ESRRB | AR 29/4885NR3C1 28/4885ESR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.